key: cord-0974175-q6px4r3j
authors: Salvi, Rachana; Patankar, Panini
title: Emerging pharmacotherapies for COVID-19
date: 2020-05-14
journal: Biomed Pharmacother
DOI: 10.1016/j.biopha.2020.110267
sha: 5731e7ffe5047158950478b269c4dd1b2d510723
doc_id: 974175
cord_uid: q6px4r3j

Novel Corona-virus Disease 2019 (nCOVID 19) is caused by a novel virulent corona virus and leads to potentially fatal virulent pneumonia and severe respiratory distress syndrome. It was initially declared as public health emergency if international concern by WHO followed by Pandemic on 12(th) March 2020. As of 10(th) April 2020, more than 1.5 million people are affected globally with around 95000 deaths. Vaccines for this deadly virus are currently under development and many drugs used for other indications have been repurposed and investigated for prophylaxis and treatment of COVID 19. As per SOLIDARITY trial by WHO, some of the most promising candidates include chloroquine phosphate and hydroxychloroquine which are anti-malarial medications, Remdesivir, Lopinavir-Ritonavir combination with or without interferon which are anti-HIV drugs and convalescent plasma therapy. The current evidence of efficacy and ongoing research has been elaborated in the article. Besides, there has been evidence regarding inflammatory pathogenesis of this virus leading to cytokine storm in susceptible individuals. Thus, anti-proinflammatory cytokine drugs like Anakinra and Tocilizumab are undergoing multiple trials and some results are encouraging. Similarly, use of anti-inflammatory cytokines like IL-37 and IL-38 is hypothesised to be useful and is under research. The situation is still evolving and hence there is yet no definitive therapy but to conclude the use of repurposed medications can be a boon till a definitive therapy and vaccines are developed.

animals, it soon became clear that efficient person-to-person transmission was also occurring.

[4] From phylogenetics analyses undertaken with available full genome sequences, bats and possibly pangolins appear to be the reservoir of COVID-19 virus, but the intermediate host (s) has not yet been identified. [5] [6]

As of 6 April 2020, over 1,280,000 cases of COVID-19 are reported in over 200 countries and territories, leading to approximately 70,500 deaths. over 270,000 people have recovered globally. [6] the primary case of the 2019-20 coronavirus pandemic in India was reported on 30 January 2020, originating from China. As of 6 April 2020, the Ministry of Health and Family Welfare have confirmed a complete of 4,067 cases, 292 recoveries (including 1 migration) and 109 deaths within the country. Experts suggest the amount of infections may be much higher as India's testing rates are among the bottom within the world. The infection rate of COVID-19 in India is reported to be 1.7, significantly less than within the worst affected countries. [7] 3. Clinical Features: 

At present clinical management includes infection prevention and control measures and supportive care, including supplementary oxygen and mechanical ventilatory support when indicated. WHO countries and counting which tests four therapy groups: Remdesivir, lopinavir-ritonavir with or without interferon, and hydroxychloroquine. the rationale for selecting these drugs was stated as there was some evidence of effectiveness against the SARS-CoV 2 virus, which caused Covid-19, either in vitro and/or animal studies. [11] As shown in in the figure, the envelope is like HIV virus consisting of spike glycoprotein S, E protein and membrane protein M which are essential for entry of virus in the cell. This is a RNA virus and thus RNA genome is present in the core. Apart from the pathophysiology of virus itself, it is now believed that the primary cause of mortality in susceptible patients is either due to pro-inflammatory cytokine storm or due to secondary bacterial infection. Secondary bacterial infections can be treated by using various antibiotics.

Research is currently focussed for innovation of new therapies to treat this potentially fatal cytokine storm. Besides, most microbes including COVID-19 are known to bind to Toll like Receptor (TLR) which in turn induces a highly proinflammatory cytokine, Interleukin 1 (IL-1). IL-1 is the mediator of fever and fibrosis. This can lead to further deterioration in susceptible COVID positive patients.

Thus, drugs supressing IL-1 or IL-1 receptor can be taken into consideration for treatment of COVID -19. [3] A study has found out that women are much less susceptible to being affected by COVID 19 compared to men. Initially, the reason was hypothesised to be only environmental stating that as smoking is more prevalent in men and hence their respiratory system is compromised leading to  In-vitro: The lopinavir/ritonavir combination was first considered a potentially useful treatment after in-vitro studies showed it had antiviral activity against SARS coronavirus. [13] J o u r n a l P r e -p r o o f  Animal model: The lopinavir/ritonavir-treated and interferon-β1b-treated animals had better outcome than the untreated animals, with improved clinical (mean clinical scores ↓50.9%-95.0% and ↓weight loss than the untreated animals), radiological (minimal pulmonary infiltrates), and pathological (mild Broncho interstitial pneumonia) findings, and lower mean viral loads in necropsied lung (↓0.59-1.06 log10 copies/glyceraldehyde 3-phosphate dehydrogenase [GAPDH]; P < .050) and extrapulmonary (↓0.11-1.29 log10 copies/GAPDH; P < .050 in kidney) tissues. [14]  Key Clinical Trial: Chan and colleagues compared outcomes in people who received lopinavir/ritonavir as initial treatment, and as rescue therapy, with matched controls; all patients were given ribavirin and steroids according to a standardised protocol. The addition of lopinavir/ritonavir as initial treatment was associated with a statistically significant reduction in the overall death rate and intubation rate compared with matched controls (p<0·05). [15] [Note: Camostat Mesylate is another drug of same class (Protease inhibitors) having same mechanism of action, has shown evidence of effectively blocking SARS-CoV-2 in lung cells in-vitro.] [5] E. Convalescent plasma:  Mechanism of Action: Tocilizumab is a recombinant humanized monoclonal anti-IL-6R antibody. It binds both soluble and membrane-bound IL-6R to inhibit IL-6-mediated cis-signalling and trans-signalling. J o u r n a l P r e -p r o o f G. Anti-inflammatory cytokines as drugs:

Though it is a member of IL-1 family and is structurally like IL-1, it has anti-inflammatory activity. IL-37 has several mechanisms for immunosuppression but it ultimately leads to suppression of IL-1. It inhibits histocompatibility complex (MHC) molecules and thus inflammation by suppressing IL-1, IL-6, TNF & CCL2. [23] Currently, there is no evidence regarding safety and efficacy of IL-37.

Like IL-37, this is one of the most recently discovered anti-inflammatory cytokine belonging to the family of IL-1. It binds to the receptor of Interleukin 1 receptor type 6 and leads to suppression of inflammation.

In-vitro cultures of activated peripheral blood mononuclear cells (PBMCs) are inhibited by IL-38 in the production of several cytokines including IL-1, IL-17 and IL-22. IL-38 gene knock out mice are more susceptible to inflammatory conditions. Currently there are no clinical trials using either IL 38 or its analogues. However, IL-38 can also be a potential new therapy.

[24]

As this is still an evolving topic, only the key medications mentioned in WHO and CDC guidelines as of 9 th April 2020 have been incorporated in this review. Besides, we have added potential immunosuppressive therapies in the review as cytokine storm is one of the most common reasons for mortality in susceptible individuals. However, there are many more drugs currently under investigation including drugs like ivermectin, Vitamin C, Baloxavir, colchicine and Tacrolimus. The efficacy and safety of these drugs is still unknown and will be clearer in the coming months.

A new challenge for prevention and therapy

How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1

Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection

Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries

Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

COVID-19) and anti-rheumatic drugs

Therapeutic Options for Patients

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

First Case of 2019 Novel Coronavirus in the United States

Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings

Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: A multicentre retrospective matched cohort study

Recommendations for Investigational COVID-19 Convalescent Plasma | FDA

Potential therapeutic agents against COVID-19: What we know so far

Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma

Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome

Search of: CC-11050 | Recruiting | Interventional Studies -List Results -ClinicalTrials.gov

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

Assessment for Evidence of COVID related treatment

Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies

Biology of IL-38 and its role in disease